Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mitchell

Showing results (1331-1340 of 1,365) with videos related to

Pageof 137
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2024
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11Vered Stearns, Opeyemi A Jegede, Victor T-S Chang, et al.
Plos Pathogens|August 31, 2013
Aspergillus galactosaminogalactan mediates adherence to host constituents and conceals hyphal β-glucan from the immune systemFabrice N Gravelat, Anne Beauvais, Hong Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast CancerBryan P Schneider, Fengmin Zhao, Tarah J Ballinger, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology|April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol EMonica F Chen, Zihe Song, Helena A Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Mbio|October 11, 2022
Nature of β-1,3-Glucan-Exposing Features on Candida albicans Cell Wall and Their ModulationLeandro José de Assis, Judith M Bain, Corin Liddle, et al.
Scientific Data|May 1, 2024
Phylogenomics and genetic analysis of solvent-producing Clostridium speciesRasmus O Jensen, Frederik Schulz, Simon Roux, et al.
JCO Precision Oncology|January 18, 2023
High PD-L2 Predicts Early Recurrence of ER-Positive Breast CancerInna Chervoneva, Amy R Peck, Yunguang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Pageof 137

Showing results (1331-1340 of 1,365) with videos related to

Sort By:
Pageof 137
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2024
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11Vered Stearns, Opeyemi A Jegede, Victor T-S Chang, et al.
Plos Pathogens|August 31, 2013
Aspergillus galactosaminogalactan mediates adherence to host constituents and conceals hyphal β-glucan from the immune systemFabrice N Gravelat, Anne Beauvais, Hong Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast CancerBryan P Schneider, Fengmin Zhao, Tarah J Ballinger, et al.
JCO Precision Oncology|April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology|April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol EMonica F Chen, Zihe Song, Helena A Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Mbio|October 11, 2022
Nature of β-1,3-Glucan-Exposing Features on Candida albicans Cell Wall and Their ModulationLeandro José de Assis, Judith M Bain, Corin Liddle, et al.
Scientific Data|May 1, 2024
Phylogenomics and genetic analysis of solvent-producing Clostridium speciesRasmus O Jensen, Frederik Schulz, Simon Roux, et al.
JCO Precision Oncology|January 18, 2023
High PD-L2 Predicts Early Recurrence of ER-Positive Breast CancerInna Chervoneva, Amy R Peck, Yunguang Sun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Pageof 137